• Pivot Pharmaceuticals attains prestigious CSE25 status
• Recent acquisitions have extended the company’s portfolio in the cannabis space
• Numerous pharmaceutical and nutraceutical products in development pipeline

Canadian biopharmaceutical company Pivot Pharmaceuticals Inc. (CSE: PVOT) (OTCQB: PVOTF) (FRA: NPAT) announced on March 19, 2018, that it has been named to the CSE25 Index (http://ibn.fm/4S2cb). CSE25 is a conglomerate of the 25 largest companies by market capitalization listed on the Canadian Securities Exchange. This achievement adds to Pivot Pharmaceuticals’ status as a constituent of the CSE Composite Index, which provides a distinctly different risk/return profile than the broad Canadian equity market.

“With an impressive pipeline of bio-cannabis products, a strong intellectual property portfolio of formulation and delivery technologies, and the expected addition of ACMPR licensed Agro-Biotech, we are proud to be recognized as leaders on the Canadian Securities Exchange through our inclusion in the CSE25 Index,” Dr. Patrick Frankham, CEO of Pivot Pharmaceuticals, stated in the news release. “Being among the top 25 performers on the exchange validates our business strategy to become a vertically integrated health and wellness company with a rapidly expanding international presence. With all of the exciting opportunities ahead of us, we believe we will remain a consistent part of the CSE25 Index for years to come as we continue to drive shareholder value.”

In February 2018, Pivot Pharmaceuticals entered into a letter of intent for the acquisition of Agro-Biotech Inc., a cannabis cultivator located in Quebec. Agro-Biotech received its producer’s license on January 12, 2018. On completion of the proposed acquisition, Pivot will be able to conduct research and development and store cannabis derivatives not currently covered under ACMPR regulations. The company will also be in a position to process natural health products and export cannabis oils and concentrates to international markets, once it receives an export permit.

The company’s recent acquisitions also include Thrudermic, LLC, a company based in North Carolina that has developed a transdermal, lipid-based nano-dispersion technology for cannabinoid delivery. Pivot also acquired ERS Holdings, LLC in February 2018, a California-based company that holds patents for the production of powderized cannabis oil that can be added to beverages and baked goods.

Pivot Pharmaceuticals is a Vancouver-based biopharmaceutical company engaged in the development and commercialization of therapeutic pharmaceuticals and nutraceuticals through proprietary drug delivery technologies via medical cannabis product division Pivot Green Stream Health Solutions (“PGS”). In early February 2018, the company announced that it had filed three provisional patents for cannabinoid-based product delivery technologies with the U.S. Patent Office. These are for its innovative transdermal nanotechnology, inhalation and mucus topical delivery platforms. Its BiPhasix™ Transdermal Drug Delivery technology has been tested in clinical trials approved by both the FDA and EMA. This delivery platform provides significant advantages over oral delivery technologies.

Pivot has a number of products in its pipeline that are in various stages of development. These target therapies for pain, inflammation, dermatology, eye disease and cancer supportive care. PGS-N005 is a cannabidiol (CBD)-based topical cream to treat female sexual dysfunction, a disorder that is estimated to affect up to 63 percent of women in the United States (http://ibn.fm/0iuTk). The market for female sexual dysfunction disorder therapies is estimated to be more than $4 billion.

For more information, visit the company’s website at www.PivotPharma.com

• ETST revenue increased by 90 percent in the month of February
• Research demonstrates that ETST’s CBD oil offers top nutritional and supplement value
• Newly appointed chief sales officer and chief learning officer opening innovative avenues

Earth Science Tech, Inc. (OTC: ETST) announced on March 13, 2018, that February marked the company’s highest-ever sales revenue month. The innovative biotech company focuses on cannabidiol (CBD) nutraceutical and pharmaceutical fields, along with its provision of R&D for certain medical devices. In February, the company achieved a 90 percent revenue increase, from $39,881 to $75,981. The company attributed this increase to its new veteran chief sales officer, supported by a CBD line that has undergone a revamp (http://ibn.fm/Ku6FU).

Earth Science Tech possesses among the highest quality and purity full-spectrum hemp CBD oil on the market. The product is made through critical CO2 extraction processes, making ETST’s CBD oil 100 percent organic and natural. Working alongside DV Biologics and the University of Central Oklahoma, ETST’s research demonstrated that the company is the top nutritional and supplement brand for high-grade hemp CBD oil (http://ibn.fm/CUozW).

In a news release, Nickolas Tabraue, company president, director and COO, noted February to be a pivotal month, giving praise to newly appointed CSO Jill Buzan while appointing Gabriel Aviles as the company’s chief learning officer. “Jill Buzan has brought so much to our company, and with her experience and knowledge Earth Science Tech, Inc. truly looks to stay innovative and be the trusted CBD brand in the industry,” Tabraue stated, further mentioning that Aviles has begun recording live videos from Monday through Friday on the company’s YouTube channel. Through this endeavor, individuals will have the opportunity to learn more about CBD and will be able to ask questions in real-time, with the videos being shared on social media.

Commenting on the achievement, CSO Jill Buzan stated, “My first month with the company has been an amazing experience with so much potential. I’m excited to see that we were able to achieve the highest revenue month to date, especially due to product delivery delays and slight errors made from the manufacture.”

Tabraue confirmed that the new product revamp has been successful, despite minor errors and manufacturing delays resulting from the increased product demand that was experienced. “We are currently working on our next batch, improving our formula and providing adequate manufacturing time to eliminate any potential errors and to prevent backorders,” Tabraue continued.

Tabraue goes further to say that ETST’s audit continues to move forward and is set to be finalized before the end of March. The audit will be used to submit the company’s planned Tier II Regulation A+ offering, alongside its planned OTCQB up listing. “The team and I greatly appreciate our stakeholders’ loyalty, trust and support while growing with us. We plan on sharing updates as they progress,” reaffirmed Tabraue. With February proving to be a fiscal milestone for Earth Science Tech, Inc., it can be expected that the newly introduced leadership will bring further innovative changes within this fast-growing industry.

For more information, visit the company’s website at www.EarthScienceTech.com

• CIIX acquires equipment to participate in cryptocurrency mining; installing AntMiners and ASIC machines in secure datacenter, it intends to explore feasibility of earning coins such as bitcoin and Litecoin
• Warren Wang, CEO of CIIX, said that the move positions the company to capitalize on the growing blockchain industry; firm already has a daily broadcast on cryptocurrencies and sponsors bitcoin ATM
• CIIX may add graphical processing units (GPUs) and more mining equipment in the future

ChineseInvestors.com, Inc. (OTCQB: CIIX) is doubling down on its commitment to cryptocurrency. The company recently announced that it has acquired various pieces of equipment, including AntMiners, and installed them inside of a secure datacenter near Seattle. CIIX intends to use this equipment to explore blockchain mining (http://ibn.fm/Pu6LL).

CIIX said that, based on initial reports, it believes that cryptocurrency mining will result in a successful venture. If this forecast proves correct, CIIX anticipates ordering 500 or more application specific integrated circuit (ASIC) units. Additionally, the company would consider purchases of graphical processing units (GPUs) and other equipment used for blockchain mining.

The goal of these efforts is to achieve minimum hash rates that are consistent with the equipment specifications by the end of CIIX’s fiscal year on May 31, 2018. ASIC chips are seen as the ‘hashing workhorses’ of AntMiner units (http://ibn.fm/8TbwI).

CIIX is a company focused on educating and informing its global Chinese-speaking audience on a variety of financial subjects. It also has a core consulting business that manages brand building and roadshows for clients.

Prior to this new focus on the exploration of actual cryptocurrency blockchain mining, CIIX had already assumed a leadership position in this industry. It hosts a bitcoin ATM in the lobby of its San Gabriel, California, headquarters. It also broadcasts a daily video from the floor of the NYSE, titled ‘Bitcoin MultiMillionaire’, reporting on cryptocurrency news. Additionally, CIIX maintains an online crypto news website at www.NewCoins168.com.

In a news release, Warren Wang, CEO of CIIX, explained, “The Company endeavors to be on the cutting edge of blockchain technology and to stay ahead of the curve in an effort to continue to build shareholder value and increase revenues this year… This initial step into cryptocurrency mining positions the company to capitalize on a growing industry which could have tremendous upside potential.”

For more information, visit the company’s website at www.ChineseInvestors.com

Let us hear your thoughts: ChineseInvestors.com, Inc. Message Board

• Using a proprietary technology platform in development of immunotherapy treatments to fight cancer
• Company recently announced proposed investment by leading biotech funds and concurrent non-brokered financing for combined gross proceeds of up to $4.8 million
• Using social media to raise awareness and expand patient recruitment for Bria-IMT™ clinical trials

BriaCell Therapeutics Corp. (TSX.V: BCT) (OTCQB: BCTXF) is an immune-oncology biotechnology company developing immunotherapy treatments for cancer through a process which uses the body’s own immune system to destroy cancer cells, creating a safer and more manageable treatment than those previously available. BriaCell is dedicated to enhancing the lives of individuals who are facing limited therapeutic options through the use of its proprietary technology platform. The mission of the company is to develop the most cutting-edge technology available to fight cancer. This technology offers a higher level of safety and effectiveness than chemotherapy and with lower levels of recurrence.

On March 9, 2018, the company announced (http://ibn.fm/HjhsN) plans to enter into a securities purchase agreement of convertible notes, for the amount of $800,000, with a leading group of institutional and family office funds focused on biotech sector investments. At the same time, BriaCell announced its intention to complete a non-brokered private placement of units, with gross proceeds totaling up to C$4,000,000. In addition, the company has received an investment from a leading biotech family office in the U.S. The combined proceeds will be used to finance BCTXF’s phase IIa clinical trial, as well as to finance the pursuit of additional research opportunities and to create working capital and fund corporate purposes.

Bria-IMT™ is the company’s lead product and is a potentially safe and effective option for those with advanced breast cancer. It has also been shown to reduce the size of tumors in the lung and brain. The company recently appointed a social media marketing company, Akari Health, to help improve patient enrollment in the Phase I/IIa clinical trial and the rollover study. The goal is to raise awareness of Bria-IMT™ and accelerate patient recruitment and retention.

For more information, visit the company’s website at www.BriaCell.com

• Cobalt prices more than doubled in 2017, with battery production driving demand
• Global cobalt supply shortage likely brewing with world’s increasing shift to electric vehicles
• Concerns continue over illegal cobalt mining operations and child labor in geopolitically unstable Democratic Republic of the Congo

The world’s appetite for electric vehicles and battery-driven mobile technologies appears to be insatiable, and this demand could generate cobalt supply problems in the not-too-distant future (http://ibn.fm/7RvYJ). Several of the world’s biggest auto companies and tech giants are reportedly looking to bank vast amounts of the metallic element in a bid to secure long-term cobalt supplies (http://ibn.fm/rASCW).

First Cobalt Corp. (TSX.V: FCC) (OTCQB: FTSSF), a leading cobalt explorer in North America, is making its own play to provide conflict-free cobalt to the market, a direct reference to global concerns raised over the geopolitical instability and child labor practices of the Democratic Republic of the Congo. The Congo, which produces roughly 60 percent of the world’s cobalt, recently declared cobalt and coltan as ‘strategic minerals’ and imposed a 10 percent royalty fee (a jump from 2 percent), payable to the government (http://ibn.fm/J3LYB).

As the largest landowner in Canada’s prominent Cobalt Camp and a leading explorer for cobalt in the region, First Cobalt Corp. is expanding its potential as a provider of clean, conflict-free cobalt (http://ibn.fm/tqAp9) with an agreement to acquire the Idaho-based cobalt assets of US Cobalt Inc. (TSX.V: USCO) (OTCQB: USCFF). The transaction further enhances the company’s position as a pure-play North American cobalt company, as First Cobalt president and CEO Trent Mell noted in a news release.

“We foresee a shortage of cobalt over the next five years yet there are few companies doing significant work to identify new sources of supply,” Mell said in announcing the deal. “This transaction creates a larger platform to discover and develop cobalt projects for the growing electric vehicle market by combining high quality North American assets in two of the best cobalt jurisdictions outside the DRC. US Cobalt’s Idaho project complements our Canadian Cobalt Camp properties, offering upside potential for shareholders of both companies.”

Cobalt prices, which more than doubled from 2016 to 2017, were up 133 percent year-over-year in February 2018, with analysts predicting that prices will continue a choppy, although rising, growth pattern through 2022 (http://ibn.fm/RWbXS). Miners spent more than $8 billion searching for new metal deposits in 2017, about 15 percent more than in 2016, according to a report published by S&P Global Market Intelligence, with spending on cobalt exploration increasing at quadruple rates (http://ibn.fm/OvSxX).

A metallurgical study now underway to potentially utilize First Cobalt’s mill facility in the Canadian Cobalt Camp is expected to advance the company’s understanding of its processing options on the crush waste rock material and high-grade inventory of refinery residue located on site.

“While we continue to advance our exploration strategy, another key strategic objective is to seize upon the opportunity to generate early cash flow from material left on surface from historic mining operations,” Mell said in a news release (http://ibn.fm/Da8e2). “This study is an important step toward our goal of producing cobalt battery materials in North America.”

For more information, visit the company’s website at http://ibn.fm/FTSSF

Let us hear your thoughts: First Cobalt Corp. Message Board

• Financial portal offering quant tools to small investors
• Reports on over 50,000 global equities and North American ETFs
• Financial news from Euronext, The Wall Street Journal, Thomson Reuters, Yahoo Finance, et al

Overpowered by the rise of the machines in the financial markets, individual stock pickers have retreated. A recent report from JP Morgan estimates that just 10 percent of trading volume today can be attributed to fundamental discretionary traders (http://ibn.fm/JRVgb). Deploying powerful algorithmic strategies, institutional investors have routed small investors and driven them from the field. The decimation of the individual investor community has been relatively rapid. “50 years ago, some 90 per cent of stocks on the New York Stock Exchange were held by individuals trading on their own account,” according to the Financial Times. If this trend continues, the demise of the small investor is imminent. However, reports of that death may be greatly exaggerated, since tech company AnalytixInsight Inc. (TSX.V: ALY) (OTCQB: ATIXF) is providing the small guy with the same arsenal of tools wielded by large individual funds. The company has developed proprietary, machine-learning technology to help individual investors research and invest, giving small investors their own personal quant machine.

Available on its own dedicated website, AnalytixInsight’s flagship product, CapitalCube.com, is a financial portal that provides comprehensive analysis, including on-demand fundamental research, portfolio evaluation and screening tools on over 50,000 global equities and North American ETFs (Exchange-Traded Funds). CapitalCube generates investment ideas by providing in-depth analysis, peer-to-peer performance evaluations, accounting and earnings reports, dividend strength and AI-supported information about likely corporate actions such as dividend changes, share buybacks and acquisitions.

The CapitalCube control panel displays a mix of tables and text on each security selected. At the top, appears the appreciation (or fall) in the security over one month and one year expressed as a percentage; its 52-week price range; its fundamental score and the dividend quality store (if applicable), among other measures. Below the tables, an overview and interpretation of the numbers is set out. This means that, unlike Google Finance or Yahoo Finance, CapitalCube does not simply throw numbers at the investor but articulates their meaning in simple language.

For example, an analysis of Facebook stock using CapitalCube turns up some interesting metrics. Facebook’s ‘fundamental score’ (determined by proprietary algorithms) is 81, above average since the peer median is 50. Its current price-to-book ratio of 5.42 is about median in its peer group, and, despite its relatively high returns, the company’s growth expectations are limited. There’s a lot more data available. CapitalCube offers pronouncements on Facebook’s capital investment and debt levels, return on assets, profit margins, changes in its price-earnings ratio and a host of other areas.

The site offers three subscription options. Free access that provides basic financial information is available on signup. For individual investors, expanded access to quant tools is available for $24.99 per month or $249.00 per year. Its premium package, offering detailed reports on companies, is available for $299.00 per month or $2,999.00 annually.

The CapitalCube portal also publishes 3,000 articles daily and has multi-language capabilities. Content partners include Africa Investor, Euronext NV, The Wall Street Journal, Thomson Reuters and Yahoo Finance.

In February 2018, AnalytixInsight was named a ‘Top 10 Technology Company’ on the TSX (Toronto Stock Exchange) Venture Exchange 50 (http://ibn.fm/7zVK6). According to CEO and Chairman Prakash Hariharan, this recognition reflects the company’s several accomplishments during 2017. These include the acquisition of Euclides Technologies, the advancement of the joint venture with Intesa Sanpaolo to launch the Marketwall mobile trading app, the posting of record revenues and the attainment of operating profitability targets during the third quarter.

The company plans to present at the MicroCap Conference on April 9-10 in New York City at Essex House (http://ibn.fm/on8sV).

For more information, visit the company’s website at www.AnalytixInsight.com

Let us hear your thoughts: AnalytixInsight Inc. Message Board

• Poised to revolutionize smokeless tobacco
• Proven effective in cannabinoid delivery, undergoing testing for nicotine
• An enabling tech seeking third-party partnerships within the tobacco industry

Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) is helping smokers light up less. Using LXRP’s revolutionary technology, smokers could be able to give up smoking without giving up nicotine. With one billion smokers worldwide, companies are seeking safer delivery technologies to help wean smokers from this deadly habit. Through third-party partnerships with major tobacco industry players, LXRP is poised to revolutionize smokeless tobacco (http://ibn.fm/2iqhO).

Lexaria is gaining prominence for its proprietary delivery technology. The company’s DehydraTECH™ technology, already proven effective in cannabinoid delivery, is undergoing testing for nicotine. Smoking is harmful due to the 4,000 chemicals released when the tobacco is lit up, even though the amount of nicotine absorbed by smokers represents a minimal hazard. Inhalation through the lungs is not healthy. Non-combusted food and drink through the human GI have been found to be much safer. However, previous methods of infusing tobacco in gum, mints or coffee have irritated the gastrointestinal tract, creating cramps and other symptoms, and required sweeteners to mask the bitter taste.

LXRP’s technology enables the delivery of bioactive substances via oral ingestion without the need for the unhealthy practice of inhalational dosing or the addition of unhealthy sugars or sweeteners. In addition, DehydraTECH acts as a Trojan horse, allowing the drug to enter the GI tract, and it is expected to reduce or eliminate uncomfortable side effects that smokers have experienced through previous edible food formats. DehydraTECH is powerful at accelerating intestinal absorption, having already been proven to decrease delivery-time to the bloodstream of edible cannabinoids from the previous 60-90 minutes to a mere 10-15 minutes.

Following its established model in the cannabis industry, Lexaria’s aim is to partner with tobacco companies rather than compete with them. It is an enabling tech, not a competing tech. In the cannabis industry, the company has entered into a licensing agreement with Biolog, Inc. (a Utah-based company not to be confused with a California cell phenotyping company of the same name) to create a unique set of next-generation food and beverage cannabis-infused products for the U.S. market. LXRP also recently entered into an agreement with Cannfections Group Inc. to create cannabis-infused chocolates and candies for the Canadian market.

Lexaria is now looking to out-license its DehydraTECH to third-party partners in the tobacco industry. These partnerships could pave the way for a healthier smoke-free option for the one billion smokers worldwide. Lexaria is the only company in the world that holds a patent for this oral technology, including the pill. A new U.S. patent award protects this nicotine delivery system, creating a path for what could be the world’s first nicotine edibles for the smokeless tobacco industry.

For more information, visit the company’s website at www.LexariaBioscience.com

Let us hear your thoughts: Lexaria Bioscience Corp. Message Board

• FanDom retains services of corporate communications firm NetworkNewsWire
• NNW will leverage powerful distribution network and sizable social media following to maximize company’s exposure throughout the investment community
• FanDom launched beta version of Android app earlier this month

FanDom Sports Media Corp. (CSE: FDM) (OTC: FDMSF) (FRANKFURT: TQ42), an aggregator, curator and producer of unique fan-focused content delivered through its mobile app, recently announced that it has retained the services of corporate communications firm NetworkNewsWire (“NNW”). NNW is a strategic communications trendsetter with a client base that ranges from start-ups to established industry leaders. Leveraging a powerful distribution network and an extensive social media following, NNW will aim to maximize exposure for FanDom throughout the investment community as the company works to achieve its goal of an optimized conversion rate of far-reaching messaging, effectively translating app downloads into engaged users.

“NNW provides us with a network of relationships which attracts the audience that our company strives to engage, not just from a brand awareness and user acquisition standpoint but also from a fresh shareholder base perspective,” Henri Holm, president and CEO of FanDom, stated in a recent news release. “Our goal is to establish a significant presence among the investment community along with synergistic and competitive industry players. Through their use of the latest social networking tools and advanced SEO capabilities, NetworkNewsWire has the proven ability to broaden FanDom Sports’ influence.”

FanDom’s decision to retain the services of NNW comes at what is a transformative time for the company. In a November 2, 2017, news release, FanDom announced plans to release an Android version of its mobile app, in beta form, by the end of the first quarter. On March 12, 2018, the company made good on these plans, releasing the beta app ahead of schedule. As FanDom noted in a news release detailing the launch, “After a kick-ass and much faster than anticipated Alpha testing phase (As per March 6, 2018 press release) we tricked this thing out and now it’s time to kick it out of the nest.”

The company notes that this beta testing process, which coincides with what it calls a friendly user-testing undertaking or ‘FUT U’, was previously successful ahead of the full commercial launch of the iOS version of its app in late 2017. Per Fandom’s news release, “Feedback from the Beta and FUT U participants will help us polish this beast and have it looking downright sexy for the commercial production release.”

For more information, visit the company’s website at www.FanDomSportsMedia.com

Let us hear your thoughts: FanDom Sports Media Corp. Message Board

• ZenaPay Payment Option Costs Merchants Less
• ZenaPay Downloads Cross 25,000 Mark
• Exciting New Development to be Announced by Company on May 30, 2018

Though cash is no longer king, being a merchant still means that you have to pay to be paid. About three-quarters of payments are made by either debit or credit card, and those payments come at a cost, which varies. This cost, known in the trade as interchange fees, encompasses the charges that a merchant must incur to have his transactions processed by the card networks, such as Visa and MasterCard. The average interchange rate for a credit card payment is around 1.81 percent, while the typical interchange fee for debit cards is 0.3 percent. However, some merchants may pay 3 percent and more of transaction volume. These, especially, will be happy to know that Epazz, Inc. (OTC: EPAZ) is offering a way to accept payments that is not only as reliable and secure as having a merchant account, but also less costly. Through its ZenaPay mobile payment system, consumers will be able to purchase bitcoin at point-of-sale and use the cryptocurrency to make their purchases.

In a recent interview (http://ibn.fm/REtrs), a spokesperson for Epazz explained the merits of the innovative app. Through fintech subsidiary ZenaPay, Epazz is offering consumers a unique, secure and reliable app, which allows them to acquire bitcoin at the point-of-sale. Essentially a payment app, ZenaPay then allows the consumer to use the digital currency to make purchases and payments. Since transactions are carried out with bitcoin, they don’t need to be legitimized, authenticated or administered by a trusted third party or intermediary that will charge fees for its services. Therefore, merchants that sign on to ZenaPay can cut costs and improve their bottom lines.

ZenaPay also comes with a ‘wallet’ that allows bitcoin to be stored for later use. Since its release in November 2017, the ZenaPay bitcoin wallet has gained widespread acceptance. On March 1, 2018, Epazz announced that the ZenaPay Bitcoin Ethereum Wallet App surpassed 25,000 downloads. A recently released version now supports ethereum and other cryptocurrencies, in addition to bitcoin, and Epazz plans to provide support for LiteCoin and SegWit in future releases. The app can be integrated with another innovative app, CryptoFolio, which Epazz has acquired.

CryptoFolio is an app with the capability to track and manage bitcoin and altcoin portfolios. Epazz, Inc. has acquired the software rights, source code and user base of CryptoFolio, and the company plans to add additional cryptocurrencies and languages to the app, along with an iOS version to attract more users. CryptoFolio, designed for business enterprise, provides free features to attract users and then allows them to purchase additional features ranging in price from $1.99 to $5.99 each.

Epazz also offers an iOS app called Bitcoin Charts, which provides live trading data on cryptocurrencies. The company plans to combine the newly acquired CryptoFolio tracker app with the Bitcoin Charts iOS app to create the ultimate live cryptocurrency trading app. The combined app is expected to be available on both the App Store and Google Play soon, and it will eventually be translated into 10 different languages. The next release of Cryptofolio, which will incorporate features from the charts and tracker apps, is set for May 30, 2018.

For more information, visit the company’s website at www.Epazz.com

Let us hear your thoughts: Epazz, Inc. Message Board

• NCMI is an integrated digital media company that focuses on terrestrial and satellite network technology, making its network efficient and scalable
• Seeking Alpha financial expert Julian Lin believes that NCMI’s PPS will rise in 2018 due to larger theater audiences and the financial impact of its MoviePass creating a ‘significant tailwind’ for the stock
• Company integrates marketing – bundling on-screen, lobby, online and mobile exposure
• Noovie brand is designed to connect brands with movie audiences both in and out of theaters

In spite of its reported decline in revenue for 2017, National CineMedia, Inc. (NASDAQ: NCMI) expects generally better conditions in 2018, forecasting annual revenue gains of up to 4.5 percent. NCMI also said that it expects to receive $23 million this year related to integration and other encumbered theater payments, from Cinemark and AMC, associated with the Rave Theatres and Carmike Theatres acquisitions (http://ibn.fm/LglN8).

NCMI holds a 48.8 percent interest in and is the managing member of National CineMedia, LLC. It produces the Noovie brand pre-show in 49 national and regional circuits. Its advertising network includes more than 20,800 screens in more than 1,700 theaters. It has 20-year agreements with the three largest theater circuits in the U.S., according to its 2018 investor presentation (http://ibn.fm/Bt9rZ).

In an article published by Seeking Alpha, financial analyst Julian Lin affirmed a buy rating for the company’s stock, despite NCMI’s recent drop in share price related to the company cutting its dividend. “My 12x price target is $12 which is 15 times free cash flow and a 5.6% yield,” Lin wrote in the article. “Including the 68-cent dividend, this is a 108% total return.” In the article (http://ibn.fm/ZQywU), titled ‘National CineMedia: Wall Street Forgot About MoviePass’, Lin asserts that the investment community “has greatly underestimated the rapidly improving environment for the theater advertising industry.”

He added that MoviePass would have numerous benefits to NCMI in the future. MoviePass’s revamped and lower pricing helped it expand its reach to two million subscribers in January 2018. Lin predicts that this will mean increased theater traffic that may result in increased advertiser demand. The result, he said, is a ‘significant tailwind’ for NCMI stock.

For more information, visit the company’s website at www.NCM.com